Leonard Schleifer
CEO and Founder, Regeneron Pharmaceuticals
$3.5B
as of 10/04/24
About Leonard Schleifer
Leonard Schleifer cofounded drugmaker Regeneron in 1988, and remains CEO of the Tarrytown, New York-based company.
Schleifer took Regeneron public in 1991; he owns 2% of the company's common stock.
Sales of Regeneron's blockbuster drug Eylea, a treatment for macular degeneration, reached $5.7 billion in the U.S. in 2023.
Regeneron has developed 12 FDA-approved medicines.
Regeneron is working on antibody medicines to prevent and treat people with Covid-19.
Personal stats
Citizenship
United States of AmericaSource of wealth
PharmaceuticalsResidence
Tarrytown, New YorkMarital status
MarriedBirth date
07/07/52 (age 72)Number of children
3Education
Bachelor of Arts/Science, Cornell University; Medical Doctor, University of Virginia; Ph.D, University of VirginiaSelf-made
self-madeLeonard Schleifer’s fortune is worth
58K
troy ounces of gold
54K
median U.S. household
35K
median U.S. income
0.07%
U.S. credit card volume
0.014%
GDP of the United States
0.01%
United States debt
Net worth history
Annual ranking
Did you know?
The son of a sweater manufacturer, Schleifer grew up in Queens, New York.
Net worth over time
Real-time ranking
Financial assets
NASDAQ | REGN-US
Regeneron PharmaceuticalsNASDAQ | REGN-US
Regeneron PharmaceuticalsNASDAQ | REGN-US
Regeneron PharmaceuticalsNASDAQ | REGN-US
Regeneron PharmaceuticalsNASDAQ | REGN-US
Regeneron PharmaceuticalsNASDAQ | REGN-US
Regeneron PharmaceuticalsImages © Forbes.com. All rights reserved.